WELCOME TO The PHARMACEUTICAL REPORT
Newsletter | Member Login | Signup
Home > Companies > OBS Pakistan Pvt. Ltd.
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Conference
Business Insights
Qualigen Therapeutics, Inc. | June 03, 2022
Qualigen Therapeutics, Inc. a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces it has completed the acquisition of a majority stake in NanoSynex Ltd., an Israeli-based developer of next generation diagnostics technology. NanoSynex’s award winning technology is an Antimicrobial Susceptibility Testing (AST) platform that aims to ...
Research
Two Labs | July 08, 2021
Two Labs, an industry-leading pharma services company and a subsidiary of Envision Pharma Group, announced today the acquisition of Riparian, a pharma consulting and SaaS company that assists manufacturers with pricing regulations, reporting, strategies, and program operations. The acquisition expands Two Labs' pharma service offerings, allowing the company to offer greater insights into the financials associated with drug launch and management, better positioning manufacturer...
FUISZ LLC | April 19, 2022
The first patent for Fuisz Pharma LLC's non-invasive urological device platform to alleviate symptoms of BPH, US 11,213,41, entitled "Device and Method for Reducing Urinary Retention," was issued via Fuisz LLC. Fuisz Pharma LLC is still looking for additional patent protection to go along with the one that was obtained. The Fuisz device is non-invasive, simple to use, and has been shown to help initiate urination, minimize dribbling and nocturia, and decrease urine r...
Fiercepharma | April 29, 2020
As headlines multiplied and analysts began sussing out Gilead Sciences' first controlled trial readout on remdesivir, NIAID director Anthony Fauci hailed the drug as real progress against the virus. Meanwhile, word emerged that the Trump administration is working up a Manhattan Project style vaccine initiative, bringing biotech, pharma and federal agencies together to speed up the work—and let the U.S. government take on the financial risks. Plus, Pfizer and BioNTech said they've d...
Business Insights, PHARMA TECH
Video
Research, Business Insights
Pharma Tech
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE